Transenterix, inc. (TRXC)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12
Operating Activities
Net loss

-148,274

-154,201

-146,910

-69,343

-83,420

-61,777

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-122,481

-

-119,567

-120,524

-49,741

-46,948

-41,448

-39,054

-40,293

-37,652

-37,604

-37,362

-31,060

-28,358

-24,058

-20,349

-18,065

-15,425

0

0

0

Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:
Loss from sale of SurgiBot assets, net

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense related to Share Exchange

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Depreciation

-

-

-

-

-

2,420

2,546

2,621

2,614

2,486

2,260

2,032

1,909

1,942

1,944

1,532

1,423

1,248

673

981

911

807

855

880

917

983

1,333

2,326

2,023

1,713

0

0

0

Amortization of intangible assets

10,254

10,301

10,378

10,494

10,652

10,868

10,958

10,105

9,049

7,858

6,799

6,687

6,786

6,967

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt discount and debt issuance costs

1,183

1,513

1,587

852

781

725

873

962

753

510

249

121

156

177

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of short-term investment discount

107

327

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

0

0

-

-

-

-

39

0

0

0

Stock-based compensation

10,442

11,500

12,033

11,132

10,147

9,000

8,451

7,603

6,773

7,078

6,496

6,235

5,744

5,033

4,781

4,121

3,840

3,311

2,210

2,305

2,334

1,840

2,475

2,013

1,281

941

553

249

297

343

0

0

0

Interest expense on deferred consideration - MST acquisition

552

756

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred tax benefit

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on disposal of property

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-48

0

0

0

Deferred tax benefit

-

-

-

-

-

-3,377

-3,580

-3,520

-3,332

-3,300

-3,157

-3,485

-3,775

-5,562

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Fair Value Adjustment of Warrants

-2,100

-2,200

-13,100

-3,800

16,229

14,300

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of contingent consideration

9,500

9,600

10,770

481

627

1,000

-881

-3,012

-1,426

-2,026

-8

865

-853

-482

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

-5,872

-6,083

-1,350

3,655

7,058

7,225

5,529

656

-76

381

0

0

0

-

-

-

-

-133

-38

-88

1

-55

-301

-102

-257

-402

0

0

0

-

-

-

-

Interest receivable

-

-

-

-

-

-54

28

40

0

-23

-82

-46

-2

6

0

0

0

-

-

-

-

-67

-10

2

73

52

0

0

0

-

-

-

-

Inventory Adjustments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Gain on sale of TruePosition investment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Inventories

12,846

16,404

15,010

10,886

6,162

2,145

738

3,679

3,265

2,981

8,283

3,526

5,232

6,647

0

0

0

-

-

-

-

-701

-498

-1,076

-890

-731

-806

-1,421

-254

143

0

0

0

Other current and long term assets

-1,932

655

2,665

5,919

4,159

325

867

-30

1,926

3,348

2,692

2,788

1,647

1,528

314

-365

-453

-728

177

7

-151

170

42

336

454

328

0

0

0

-

-

-

-

Accounts payable

-445

-668

756

2,862

1,270

767

165

1,782

11

-531

-38

232

276

-356

-1,805

-1,239

-805

1,096

-513

-2,010

420

-36

0

0

0

-

-

-

-

-

-

-

-

Other current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-58

-139

0

0

0

Accrued expenses

905

-1,180

751

1,039

2,487

2,134

1,830

2,124

383

2,093

1,487

782

716

1,112

1,076

4,821

4,749

5,371

4,140

353

95

363

713

1,141

801

868

0

0

0

-

-

-

-

Deferred revenue

-679

-959

-403

-68

714

825

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other long term liabilities

-244

998

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued Interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net cash and cash equivalents used in operating activities

-61,766

-73,484

-71,968

-68,841

-60,389

-48,493

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Investing Activities
Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

0

-

-

-

-

Net cash and cash equivalents used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-51,466

-

-51,449

-50,169

-45,414

-38,759

-33,718

-36,117

-35,108

-33,353

-31,399

-27,155

-24,100

-21,236

0

0

0

-

-

-

-

Proceeds related to sale of assets, net

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of short-term investments

1,989

12,883

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from maturities of short-term investments

25,000

65,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of property and equipment

321

437

672

601

670

770

568

527

1,283

1,566

1,971

2,241

1,709

1,361

1,384

1,440

1,232

1,234

1,276

1,575

2,142

2,174

2,279

2,137

1,495

1,377

0

0

0

-

-

-

-

Purchase of investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8,150

0

0

0

Proceeds from sale and maturities of investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,191

6,188

6,188

1,719

904

8,005

8,005

8,005

7,098

0

0

0

Proceeds from sale of property and equipment

-

-

-

-

-

32

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment received under Rule 16b

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net cash and cash equivalents (used in) provided by investing activities

38,655

67,645

33,825

-15,723

-28,788

-53,481

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Financing Activities
Proceeds from issuance of common stock, preferred stock and warrants under 2020 financing, net of issuance costs

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash and cash equivalents provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-1,709

-

-1,384

-26,440

-26,232

-26,234

-26,276

-1,550

5,422

4,042

-1,261

-1,943

-8,840

-6,467

0

0

0

-

-

-

-

Capital contributions

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Proceeds from notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Payment of notes payable

-

-

-

-

-

-

-

-

-

13,343

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Payment of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

2,877

0

0

0

-

-

-

0

-

-

-

-

Proceeds from issuance of common stock and warrants, net of issuance costs

36,989

25,777

23,725

277

268

279

46,312

48,388

72,286

77,579

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided in connection with the acquisition of SafeStitch LLC

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Proceeds from issuance of common stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

87,939

-

0

0

0

-

-

-

-

-

-

-

-

-

-

0

0

Proceeds from issuance of preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

268

0

0

0

Taxes paid related to net share settlement of vesting of restricted stock units

33

499

0

0

0

-

-

-

-

-

-

-

-

168

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock related to sale of SurgiBot assets

-

-

-

-

-

3,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options and warrants

302

538

1,546

3,124

10,927

12,403

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) increase in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash and cash equivalents provided by (used in) financing activities

19,358

-5,609

19,046

10,472

21,466

26,452

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Effect of exchange rate changes on cash and cash equivalents

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from stockholder loans

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Repayment of stockholder loans

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Proceeds from exercise of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net cash and cash equivalents provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

23,231

-

52,672

70,215

96,475

68,404

68,418

56,088

56,847

53,938

0

0

0

-

-

-

0

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-49

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase in cash, cash equivalents and restricted cash

-3,382

-11,084

-19,607

-74,479

-68,290

-75,955

11,542

62,333

70,895

63,016

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options and warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

170

174

71

259

270

317

279

91

0

0

0

-

-

-

3

3

0

0

0

Net increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

20,515

50,356

-1,979

1,118

21,200

-12,797

-11,546

-5,108

0

0

0

Supplemental Disclosure for Cash Flow Information
Interest paid

1,437

2,187

2,668

2,659

2,176

1,730

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest paid

-

-

-

-

-

-

-

-

-

-

-

-

1,149

-

1,394

1,311

1,159

973

984

942

912

904

717

724

813

824

712

652

405

306

0

0

0

Supplemental Schedule of Non-cash Investing and Financing Activities
Transfer of inventories to property and equipment

2,358

486

478

1,520

2,175

2,160

0

0

0

-

-

-

-

3,198

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Exchange of common stock for Series B Warrants

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock as contingent consideration

-

-

-

-

-

-

-

-

-

5,227

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reclass of warrant liability to common stock and additional paid-in capital

-

-

-

-

-

23,774

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Transfer of in-process research and development to intellectual property

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of preferred stock to common stock

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash dividend upon issuance & conversion of Preferred

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Stock dividends

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Stockholder loans contributed to capital

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Warrants issued in connection with credit facility

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0